§ The providers
Who sells what — and who to trust.

An independent overview of the compounded-GLP-1 telehealth market and the providers we cover — market size, what the FDA changed, and an honest read on each.

View the provider overviewOverview & reviews
§ Learn
The educational layer, in progress.

Primers for newcomers and deep dives for the curious. The foundation articles are published; more are in the pipeline.

View all Learn articles
503A + 503B · Irving, TX

Carie Boyd's Prescription Shop: 503A + 503B compounder profile

A Texas dual 503A/503B compounder covering HRT, aesthetics, and weight management (including sublingual semaglutide), shipping nationwide.

Editorial independence

This profile is editorial. PeptideWellness has no commercial relationship with this pharmacy; coverage and assessment are never for sale.

Carie Boyd’s runs both a 503B outsourcing facility (office-use batches) and a patient-specific 503A pharmacy — one of the more established dual-status compounders squarely in the consumer wellness space (hormones, aesthetics, weight loss).

Facility & accreditation

The 503B facility (legal entity “Right Value Drug Stores, LLC,” Irving, TX) is on the FDA Registered Outsourcing Facilities list [1], and the company also operates a 503A patient-specific pharmacy in Denton, TX [2]. It says it ships nationwide with free 2-day shipping [2]. On accreditation, a search of ACHC’s PCAB directory did not return a listing for Carie Boyd’s [3]; the company doesn’t prominently claim PCAB, so treat accreditation as not independently confirmed.

What they compound

Relevant lines: HRT (hormone pellets, hormone injections, oral bioidentical hormones, topical creams), sexual wellness, dermatology & aesthetics, hair & scalp, anesthetics, and weight management — including sublingual semaglutide (plus naltrexone, bupropion/naltrexone, phentermine/topiramate) [2].

Regulatory record

Per the FDA 503B list, the last inspection is logged with an action status of “Regulatory Meeting Held” (2026-01-08) [1]. We found no FDA warning letter or untitled letter for Carie Boyd’s in public sources. (A third-party directory reports a Form 483 around July 2025; we could not locate the FDA primary document, so we don’t assert it.) A regulatory meeting is a step FDA uses to discuss corrections, not a finding of violation. Dated to our review; status can change.

The read

A well-established, broad-menu dual 503A/503B compounder that fits the consumer HRT/aesthetics/weight-loss audience, with nationwide shipping. No FDA warning letter on record as of our check; accreditation isn’t independently confirmable, which is the main gap versus a PCAB-verified operator like Empower.

References

  1. FDA — Registered Outsourcing Facilities (503B) list. https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities (accessed 2026-07-01)
  2. Carie Boyd’s Prescription Shop — official site. https://www.carieboyd.com/ (accessed 2026-07-01)
  3. ACHC / PCAB accredited-organization directory (searched “Carie Boyd”). https://organization.achc.org/ (accessed 2026-07-01)
§ The Daily

The peptide brief, delivered.

A 5-minute daily digest on peptide therapy news, provider updates, and regulatory changes.

Find your peptide Take 60-sec quiz